Georgiamune Inc. announced that the first cancer patient has been dosed with GIM-531 drug
Georgiamune Inc. shared a post on LinkedIn:
“Today marks an important milestone for Georgiamune. We’re proud to announce that the first cancer patient has been dosed with our GIM-531 drug. GIM-531 is a first-in-class, oral small-molecule cancer immunotherapy that selectively inhibits T regulatory cells. GIM-531 is designed to address indications and cancer types that are currently not addressed with existing or available immunotherapies.
This comes on the heels of GIM-122, a first-in-class dual-functioning antibody that’s also already in clinical trials, treating cancer patients with high unmet needs. We’re thrilled to now have two novel drugs in clinic less than a year from closing our Series A funding round. To learn more about GIM-531 and how Georgiamune is developing novel approaches to reach cancer and autoimmune disease patients around the world.”
Ramy Ibrahim, Chief Medical and Strategy Officer at Georgiamune Inc, reshared a post by Georgiamune Inc.:
“Can’t be more proud of the team who was able to take 2 novel assets into the clinic in record time. Stay tuned more to come as we are committed to bringing novel therapies to both cancer and autoimmune diseases patients working with the stellar team and scientists we have at Georgiamune Inc.”
Additional information
Source: Georgiamune Inc./LinkedIn and Ramy Ibrahim/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023